Search company, investor...

Neotropix

neotropix.com

Founded Year

2003

Stage

Series B | Alive

Total Raised

$30M

Last Raised

$20M | 14 yrs ago

About Neotropix

Neotropix 1 is a virotherapy company, dedicated to the development and commercialization of virus-based therapies for the treatment of cancer and other diseases. Per Neotropix, virotherapy holds great promise for cancer patients because it may be more efficacious and less toxic than conventional radiation and chemotherapy.

Headquarters Location

351 Phoenixville Pike 351 Phoenixville Pike

Malvern, Pennsylvania, 19355,

United States

610-296-8660

Missing: Neotropix's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neotropix's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Neotropix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neotropix is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Neotropix Patents

Neotropix has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/7/2014

Virus families, Picornaviridae, Association football defenders, Animal virology, Transcription factors

Application

Application Date

3/7/2014

Grant Date

Title

Related Topics

Virus families, Picornaviridae, Association football defenders, Animal virology, Transcription factors

Status

Application

Latest Neotropix News

Oncolytic Virus Market Present Scenario and the Growth Prospects with Forecast 2025

Mar 25, 2020

Oncolytic Virus Market report offers in-depth analysis of worldwide topmost key manufacturers ( Merck, Otsuka Pharmaceutical Co, Pfizer, Roche, Cold Genesys, Genelux, Latima, Neotropix, Shanghai Sunway Biotech, SillaJen, Takara Bio, Theravir ) to define, describe and analyze the Capacity, Production, Price, Cost, Gross, Gross Margin, Sales Volume & Revenue, Consumption, Growth Rate, Import, Export, Supply, Future Strategies, and the Technological Developments in next few years. The prime objective of this Oncolytic Virus market report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing. Oncolytic Virus market (6 Forces Forecast 2019-2025) research report offers in-intensity insight of the Oncolytic Virus industry masking all vital parameters along with Marketing Channel, Direct Marketing, Indirect Marketing, Brand Strategy, Pricing Strategy, Market Positioning, Target Client, and Distributors/Traders List. Get Free Sample PDF (including full TOC, Tables and Figures) of Oncolytic Virus [email protected]   https://www.researchmoz.us/enquiry.php?type=S&repid=2223009    Oncolytic Virus Market Forecast (2019 – 2025): Oncolytic Virus Market by Capacity, Production, Revenue Forecast, Production, Import, Export and Consumption Forecast, Production Forecast by Type and Price Forecast, Consumption Forecast by Application, Oncolytic Virus Market Production, Consumption, Import and Export Forecast by Regions (Provinces), Production Forecast by Regions (Provinces), Consumption Forecast by Regions (Provinces) Scope of Oncolytic Virus Market:  The Oncolytic Virus market report analyzes the opportunities in the global market, analyzing the data on a historical basis, estimated data for 2018, and forecasted data till the year 2025. Market analysis includes data in terms of both, value (US$) and volume (MT). The market outlook of the Oncolytic Virus market report covers feed industry overview, global industry outlook, macroeconomic outlook, and forecasted factors. The market dynamics section includes key drivers, trends, and restraints prohibiting the growth of the Oncolytic Virus market, value chain analysis, and others On the basis of product, this report displays the sales volume, revenue (Million USD), product price, Oncolytic Virus market share and growth rate of each type, primarily split into- HSV-based Oncolytic Viruses Oncolytic Virus Market Report Scope: The depth industry chain include analysis value chain analysis, porter five forces model analysis and cost structure analysis. To strategically profile the key players and comprehensively analyze their growth strategies. It describes present situation, historical background and future forecast of Oncolytic Virus Market. Comprehensive data showing Oncolytic Virus market capacities, production, consumption, trade statistics, and prices in the recent years are provided. The report indicates a wealth of information on Oncolytic Virus market manufacturers. Oncolytic Virus market forecast for next five years, including market volumes and prices is also provided. Raw Material Supply and Downstream Consumer Information is also included. Contact:

Neotropix Frequently Asked Questions (FAQ)

  • When was Neotropix founded?

    Neotropix was founded in 2003.

  • Where is Neotropix's headquarters?

    Neotropix's headquarters is located at 351 Phoenixville Pike, Malvern.

  • What is Neotropix's latest funding round?

    Neotropix's latest funding round is Series B.

  • How much did Neotropix raise?

    Neotropix raised a total of $30M.

  • Who are the investors of Neotropix?

    Investors of Neotropix include Aurora Funds, Quaker BioVentures, BioAdvance and VIMAC Ventures.

  • Who are Neotropix's competitors?

    Competitors of Neotropix include PNP Therapeutics, Forte Biosciences, GlobeImmune, MacroGenics, Somaxon Pharmaceuticals and 11 more.

Compare Neotropix to Competitors

P
PNP Therapeutics

PNP Therapeutics is dedicated to the development and commercialization of a cancer treatment approach that is predicated on well-documented evidence that solid tumors can be compelled to develop their own chemotherapy and thus elicit their own self-destruction.

O
Onyvax

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

B
BioMs

BioMs develops biologics for autoimmune diseases with a special emphasis on multiple sclerosis.

N
Novation Pharmaceuticals

Novation is focusing on the development of small molecular weight drugs that affect the stability of messenger RNA. Initial development efforts are on the treatment and prevention of cancer and chronic inflammatory diseases.

PharmAthene Logo
PharmAthene

PharmAthene's primary objective is the development of effective countermeasures to a range of biological and chemical threats having potential lethal effects for the military or civilian populations. The Company is developing Valortim, an anthrax monoclonal antibody, in collaboration with Medarex, Inc. for pre- and post exposure prophylaxis and treatment, as well as Protexia, a recombinant human butyrylcholinesterase for treatment following exposure to chemical nerve agents.

O
Osteologix

Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.